Abstract

The population structure of Mycobacterium tuberculosis is typically clonal therefore genotypic lineages can be unequivocally identified by characteristic markers such as mutations or genomic deletions. In addition, drug resistance is mainly mediated by mutations. These issues make multiplexed detection of selected mutations potentially a very powerful tool to characterise Mycobacterium tuberculosis. We used Multiplex Ligation-dependent Probe Amplification (MLPA) to screen for dispersed mutations, which can be successfully applied to Mycobacterium tuberculosis as was previously shown. Here we selected 47 discriminative and informative markers and designed MLPA probes accordingly to allow analysis with a liquid bead array and robust reader (Luminex MAGPIX technology). To validate the bead-based MLPA, we screened a panel of 88 selected strains, previously characterised by other methods with the developed multiplex assay using automated positive and negative calling. In total 3059 characteristics were screened and 3034 (99.2%) were consistent with previous molecular characterizations, of which 2056 (67.2%) were directly supported by other molecular methods, and 978 (32.0%) were consistent with but not directly supported by previous molecular characterizations. Results directly conflicting or inconsistent with previous methods, were obtained for 25 (0.8%) of the characteristics tested. Here we report the validation of the bead-based MLPA and demonstrate its potential to simultaneously identify a range of drug resistance markers, discriminate the species within the Mycobacterium tuberculosis complex, determine the genetic lineage and detect and identify the clinically most relevant non-tuberculous mycobacterial species. The detection of multiple genetic markers in clinically derived Mycobacterium tuberculosis strains with a multiplex assay could reduce the number of TB-dedicated screening methods needed for full characterization. Additionally, as a proportion of the markers screened are specific to certain Mycobacterium tuberculosis lineages each profile can be checked for internal consistency. Strain characterization can allow selection of appropriate treatment and thereby improve treatment outcome and patient management.

Highlights

  • Effective treatment of patients infected with TB relies on accurate diagnosis and appropriate therapy

  • We used an established method of multiplex single nucleotide polymorphisms (SNPs) typing which we have previously shown to be suitable for use with M. tuberculosis, the Multiplex Ligation-dependent Probe Amplification (MLPA) [28,31]

  • Markers targeting drug resistance associated mutations, mycobacterial species specific regions, M. tuberculosis genotype specific markers, as well as markers identifying epidemic strains, were included in the assay to demonstrate the versatility of this approach for the characterization of M. tuberculosis isolates

Read more

Summary

Introduction

Effective treatment of patients infected with (drug-resistant) TB relies on accurate diagnosis and appropriate therapy. It is crucial to confirm and characterise the species present in sputum cultures [1] as well as to detect drug resistance at an early stage. In many high burden settings culture of sputum samples, if performed at all, is not followed by further molecular characterisation [2]. This can lead to suboptimal treatment and patient management. Over the last years a diverse range of molecular tools have been developed to characterise and type Mycobacterium tuberculosis complex. A proportion of these methods, based on identification/detection of CRISPRs (spoligotyping), insertion sequences (IS6110 Restriction Fragment Length Polymorphism (RFLP)), large sequence polymorphisms (LSPs), Regions of Difference (RD) typing or tandem repeats (Mycobacterial Interspersed Repetitive Units-Variable Number of Tandem Repeats (MIRU-VNTR) have been widely applied [3,4,5,6,7]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call